CDH13 and hepatocellular carcinoma: In hepatocellular carcinoma, miR-665 can promote cancer cell metastasis, enhance anti-apoptotic ability, and increase the drug resistance of hepatocellular carcinoma cells to sorafenib by inhibiting CDH13.